Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rosemary A. Thornton is active.

Publication


Featured researches published by Rosemary A. Thornton.


Journal of Biological Chemistry | 1997

Khafrefungin, a novel inhibitor of sphingolipid synthesis.

Suzanne M. Mandala; Rosemary A. Thornton; Mark Rosenbach; James A. Milligan; Margarita Garcia-Calvo; Herbert G. Bull; Myra B. Kurtz

In the course of screening for antifungal agents we have discovered a novel compound isolated from an endophytic fungus that inhibits fungal sphingolipid synthesis. Khafrefungin, which is composed of aldonic acid linked via an ester to a C22 modified alkyl chain, has fungicidal activity against Candida albicans,Cryptococcus neoformans, and Saccharomyces cerevisiae. Sphingolipid synthesis is inhibited in these organisms at the step in which phosphoinositol is transferred to ceramide, resulting in accumulation of ceramide and loss of all of the complex sphingolipids. In vitro, khafrefungin inhibits the inositol phosphoceramide synthase of C. albicans with an IC50 of 0.6 nm. Khafrefungin does not inhibit the synthesis of mammalian sphingolipids thus making this the first reported compound that is specific for the fungal pathway.


Journal of Biological Chemistry | 1998

Rustmicin, a Potent Antifungal Agent, Inhibits Sphingolipid Synthesis at Inositol Phosphoceramide Synthase

Suzanne M. Mandala; Rosemary A. Thornton; James A. Milligan; Mark Rosenbach; Margarita Garcia-Calvo; Herbert G. Bull; Guy H. Harris; George K. Abruzzo; Amy M. Flattery; Charles Gill; Kenneth F. Bartizal; Sarah Dreikorn; Myra B. Kurtz

Rustmicin is a 14-membered macrolide previously identified as an inhibitor of plant pathogenic fungi by a mechanism that was not defined. We discovered that rustmicin inhibits inositol phosphoceramide synthase, resulting in the accumulation of ceramide and the loss of all of the complex sphingolipids. Rustmicin has potent fungicidal activity against clinically important human pathogens that is correlated with its sphingolipid inhibition. It is especially potent against Cryptococcus neoformans, where it inhibits growth and sphingolipid synthesis at concentrations <1 ng/ml and inhibits the enzyme with an IC50 of 70 pm. This inhibition of the membrane-bound enzyme is reversible; moreover, rustmicin is nearly equipotent against the solubilized enzyme. Rustmicin was efficacious in a mouse model for cryptococcosis, but it was less active than predicted from its in vitro potency against this pathogen. Stability and drug efflux were identified as two factors limiting rustmicin’s activity. In the presence of serum, rustmicin rapidly epimerizes at the C-2 position and is converted to a γ-lactone, a product that is devoid of activity. Rustmicin was also found to be a remarkably good substrate for the Saccharomyces cerevisiae multidrug efflux pump encoded by PDR5.


Science | 2002

Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

Suzanne M. Mandala; Richard Hajdu; James D. Bergstrom; Elizabeth J. Quackenbush; Jenny Xie; James A. Milligan; Rosemary A. Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey J. Hale; Christopher L. Lynch; Kathleen M. Rupprecht; William H. Parsons; Hugh Rosen


Proceedings of the National Academy of Sciences of the United States of America | 1998

Sphingoid base 1-phosphate phosphatase: A key regulator of sphingolipid metabolism and stress response

Suzanne M. Mandala; Rosemary A. Thornton; Zhenxing Tu; Myra B. Kurtz; Joseph T. Nickels; James R. Broach; Ramil Menzeleev; Sarah Spiegel


Proceedings of the National Academy of Sciences of the United States of America | 2000

Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death

Suzanne M. Mandala; Rosemary A. Thornton; Ismael Galve-Roperh; Samantha Poulton; Courtney M. Peterson; Ana Olivera; James D. Bergstrom; Myra B. Kurtz; Sarah Spiegel


The Journal of Antibiotics | 1995

The Discovery of Australifungin, a Novel Inhibitor of Sphinganine N-Acyltransferase from Sporormiella australis Producing Organism, Fermentation, Isolation, and Biological Activity

Suzanne M. Mandala; Rosemary A. Thornton; Beth R. Frommer; James E. Curotto; Walter Rozdilsky; Myra B. Kurtz; Robert A. Giacobbe; Gerald F. Bills; M. Angeles Cabello; Isabel Martin; Fernando Pelaez; Guy H. Harris


The Journal of Antibiotics | 1992

Sphingofungins E and F: Novel serinepalmitoyl transferase inhibitors from Paecilomyces variotii

Wendy S. Horn; Jack L. Smith; Gerald F. Bills; Susan L. Raghoobar; Gregory L. Helms; Myra B. Kurtz; Jean A. Marrinan; Beth R. Frommer; Rosemary A. Thornton; Suzanne M. Mandala


The Journal of Antibiotics | 1997

Viridiofungins, novel inhibitors of sphingolipid synthesis

Suzanne M. Mandala; Rosemary A. Thornton; Beth R. Frommer; Sarah Dreikorn; Myra B. Kurtz


The Journal of Antibiotics | 1994

Inhibition of serine palmitoyl-transferase activity by lipoxamycin.

Suzanne M. Mandala; Beth R. Frommer; Rosemary A. Thornton; Mrya B. Kurtz; Noel M. Young; M. Angeles Cabello; Olga Genilloud; Jerrold M. Liesch; Jack L. Smith; Wendy S. Horn


Bioorganic & Medicinal Chemistry | 2004

Synthesis, stereochemical determination and biochemical characterization of the enantiomeric phosphate esters of the novel immunosuppressive agent FTY720

Jeffrey J. Hale; Lin Yan; William E. Neway; Richard Hajdu; James D. Bergstrom; James A. Milligan; Gan-Ju Shei; Gary Chrebet; Rosemary A. Thornton; Deborah Card; Mark Rosenbach; HughRosen; Suzanne M. Mandala

Collaboration


Dive into the Rosemary A. Thornton's collaboration.

Researchain Logo
Decentralizing Knowledge